BrainStep Medical, a pioneering enterprise in implantable brain-computer interface (BCI) technology, has successfully concluded its Series B funding round, securing RMB 350 million. This impressive round was co-led by esteemed investors Qiming Venture Partners, OrbiMed, and Lilly Asia Ventures, with Origin Capital maintaining its ongoing support. Serving as the financial advisor for this transaction was Qifeng Capital. Notably, this funding round represents the largest sum ever raised in this sector within China. The infused capital will be strategically deployed to expedite clinical trials for BrainStep's products, foster research and development of next-generation technologies, and establish a medical-grade MEMS production base. These initiatives are aimed at propelling the clinical application and commercialization of BCI technology. BrainStep Medical remains dedicated to minimally invasive implantable BCI technology, striving to offer patients more precise and efficacious treatment options.